Experts: The development of the multi-technology route of the new crown vaccine is aimed at winning more

BEIJING, Aug. 22 (Xinhua Wang Linlin) China's Centers for Disease Control and Prevention immunization program chief expert Wang Huaqing 21 in China's medicine
the second issue of the "heart lecture hall" special lecture, said that the current global new crown pneumonia vaccine research and development technology route is roughly divided into three categories, "multi-pronged" the ultimate goal is to effective vaccine early release to win greater success.
Wang Huaqing, 29 vaccines have entered clinical trials worldwide and 138 vaccines are in preclinical research. The specific research and development routes are broadly divided into three categories: the first is the inactivated and detoxifying live vaccines of the classical technical route, the second is the protein sub-unit vaccine and the virus-like particle vaccine of the genetic recombination technology route, and the third category is the viral vector vaccine (replicated and non-replicated), nucleic acid vaccine (DNA vaccine and mRNA vaccine).
Wang Huaqing believes that inactivated vaccine research and development speed is fast, but activation of immunization may require multiple vaccinations, less anti-virus live vaccination, and long immunization time, but the research and development cycle is long, storage and transportation requirements are high, gene recombinant vaccine research and development speed, production volume, antigen stability, but technical difficulty, virus vector vaccine gene delivery efficiency, can produce a strong immune response, but no such products on the market.
Recently, the Drug Audit Center of the State Drug Administration issued five documents, such as the Technical Guidelines for the Research and Development of Vaccines for The Prevention of New Coronavirus (Trial), among which the Guidelines for clinical evaluation of vaccines for the prevention of new coronavirus (Trial) have given specific evaluation criteria for the safety, effectiveness and data of overseas clinical trials. In terms of effectiveness, the evaluation criteria specifically mention that vaccines are best protected for one year or more and at least six months.
to this, Wang Huaqing said:
National corona pneumonia for human beings is a brand-new infectious disease, its pathogenology, clinical science, epidemiology, occinology and other related knowledge are in the process of research, understanding." Ultimately which technology route can be the first to 'run through', to the market applications still need to continue to explore. "